Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 7, 2025

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.8K

Genetically Modified Porcine-to-Human Cardiac Xenotransplantation.

Bartley P Griffith1, Corbin E Goerlich1, Avneesh K Singh1

  • 1From the Department of Surgery (B.P.G., C.E.G., A.K.S., C.L.L., A.S., M.M.M.), the Program in Trauma, R. Adams Cowley Shock Trauma Center, Department of Medicine (A.G.), the Institute of Human Virology, Division of Infectious Diseases (K.K.S.), and the Department of Medicine, Division of Cardiology (S.N.H., S.M.J.), University of Maryland School of Medicine, Baltimore, and United Therapeutics, Silver Spring (M.R., M.L.) - both in Maryland; and Revivicor, Blacksburg, VA (D.A.).

The New England Journal of Medicine
|June 22, 2022
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What's Hot and What's New in Xenotransplantation From the Young Investigator Committee of the IXA-Basic and Translational Science.

Xenotransplantation·2026
Same author

Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine-to-Human Live Heart Transplant.

Xenotransplantation·2026
Same author

Case Report: When inotropy backfires-dobutamine-associated eosinophilic myocarditis.

Frontiers in cardiovascular medicine·2026
Same author

Device-Induced Blood Damage in Pump-Assisted Circulation: A Comparative Study of HeartMate III and BrioVAD Pumps.

Artificial organs·2026
Same author

TSG-6 promotes Fascin-1-Mediated Microvascular Repair in Murine Airway Allografts.

American journal of respiratory cell and molecular biology·2026
Same author

Perspectives on the 2026 ISHLT Consensus Statement on Clinical Cardiac Xenotransplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients. Reply.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
See all related articles
This summary is machine-generated.

A patient received a genetically modified pig heart xenograft. The xenograft initially functioned well but failed due to unexplained thickening and edema, highlighting challenges in xenotransplantation.

Area of Science:

  • Xenotransplantation
  • Immunology
  • Cardiology

Background:

  • A 57-year-old man with nonischemic cardiomyopathy, dependent on extracorporeal membrane oxygenation (ECMO), was ineligible for traditional heart transplantation.
  • He received a heart from a genetically modified pig with 10 gene edits, utilizing CD40 blockade for immunosuppression.

Observation:

  • The patient was successfully weaned from ECMO, and the pig xenograft initially showed normal function without rejection signs.
  • Sudden diastolic thickening and xenograft failure occurred on day 49 post-transplant, leading to withdrawal of life support on day 60.

Findings:

  • Autopsy revealed an edematous xenograft, nearly doubled in weight.
  • Histology showed myocyte necrosis, interstitial edema, and red-cell extravasation, but no microvascular thrombosis, suggesting atypical rejection mechanisms.

More Related Videos

A Preclinical Model of Orthotopic Heart Transplantation in Bama Miniature Pigs Using Biatrial Technique
06:56

A Preclinical Model of Orthotopic Heart Transplantation in Bama Miniature Pigs Using Biatrial Technique

Published on: June 13, 2025

205
A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation
09:12

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation

Published on: April 27, 2019

9.7K

Related Experiment Videos

Last Updated: Sep 7, 2025

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.8K
A Preclinical Model of Orthotopic Heart Transplantation in Bama Miniature Pigs Using Biatrial Technique
06:56

A Preclinical Model of Orthotopic Heart Transplantation in Bama Miniature Pigs Using Biatrial Technique

Published on: June 13, 2025

205
A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation
09:12

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation

Published on: April 27, 2019

9.7K

Implications:

  • This case demonstrates the potential and challenges of using genetically modified pig hearts for human transplantation.
  • Further research is needed to elucidate the mechanisms behind the observed xenograft failure and optimize future xenotransplantation strategies.